Intellipharmaceutics International Inc. (IPCIF)
| Previous Close | 0.0000 |
| Open | 0.1000 |
| Bid | 0.0259 x 0 |
| Ask | 0.1000 x 0 |
| Day's Range | 0.1000 - 0.1000 |
| 52 Week Range | 0.0213 - 0.1500 |
| Volume | |
| Avg. Volume | 103 |
| Market Cap | 4.964M |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0900 |
| Earnings Date | Sept 16, 2024 - Sept 22, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREIntellipharmaceutics Announces Downgrade to OTC Expert Market
TORONTO, ON / ACCESSWIRE / June 14, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF) and (TSX:IPCI.H) ("Intellipharmaceutics" or the "Company"), announced today that its common stock, currently traded on the OTCQB market, is expected to ...
ACCESSWIREIntellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
TORONTO, ON / ACCESSWIRE / March 13, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) - ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and ...
- ACCESSWIRE
Intellipharmaceutics Announces Cease Trade Order
TORONTO, ON / ACCESSWIRE / March 6, 2024 / Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic ...
